Bailey J E, Papadopoulos A, Lingford-Hughes A, Nutt D J
Psychopharmacology Unit, University of Bristol, UK.
Psychopharmacology (Berl). 2007 Sep;193(4):579-85. doi: 10.1007/s00213-007-0817-9. Epub 2007 May 18.
There is interest in the development of augmentation therapy in the treatment of anxiety disorders. Recent publications have shown that D-cycloserine can benefit exposure therapy in a group of acrophobic (height phobic) subjects and in patients with social anxiety disorder. These studies were based on the animal data suggesting that drugs acting to enhance glutamate function may be developed to accelerate the behavioural treatment of anxiety disorders. Perhaps by enhancing glutamate/N-methyl-D-aspartate receptor function, learning is thus enhanced. This study examines the effects of D-cycloserine 50 mg on a task that involves learning. We manipulated anxiety levels to model the effects of high anxiety.
To evaluate performance and learning, we used the Manikin task. Two groups of 24 healthy volunteers participated in a double-blind, placebo-controlled study. One group received the inhalation of CO(2) 7.5% to model high anxiety, and the second group received air to represent lower anxiety. Subjects received D-cycloserine 50 mg or placebo, and the Manikin task was performed during the gas inhalation.
There were significant differences in the group inhaling air, but not CO(2), with the D-cycloserine group showing an increase in correct responses. This difference was apparent at several time blocks during the 20-min task. These findings were supported by subjective measures in that participants who received D-cycloserine reported that the task was easier.
We have shown that at lower anxiety levels, D-cycloserine 50 mg improved the performance of this challenging visuospatial cognitive task. This increase in performance was not seen when anxiety was higher, and D-cycloserine did not appear to increase subjective anxiety. These data lend support to the use of D-cycloserine and related glutamate enhancers as cognitive modulators and suggest that the actions of D-cycloserine are not simply related to increased arousal or anxiety.
人们对开发增强疗法治疗焦虑症很感兴趣。最近的出版物表明,D - 环丝氨酸可使一组恐高症(恐高)患者和社交焦虑症患者从暴露疗法中获益。这些研究基于动物数据,表明可开发作用于增强谷氨酸功能的药物来加速焦虑症的行为治疗。也许通过增强谷氨酸/N - 甲基 - D - 天冬氨酸受体功能,学习能力就能得到提高。本研究考察了50毫克D - 环丝氨酸对一项涉及学习的任务的影响。我们通过操控焦虑水平来模拟高焦虑的影响。
为评估表现和学习情况,我们使用了人体模型任务。两组各24名健康志愿者参与了一项双盲、安慰剂对照研究。一组吸入7.5%的二氧化碳以模拟高焦虑,另一组吸入空气以代表低焦虑。受试者接受50毫克D - 环丝氨酸或安慰剂,并在吸入气体期间执行人体模型任务。
在吸入空气而非二氧化碳的组中存在显著差异,D - 环丝氨酸组的正确反应有所增加。在20分钟任务的几个时间区间内,这种差异很明显。这些发现得到了主观测量结果的支持,即接受D - 环丝氨酸的参与者表示任务更容易。
我们已经表明,在较低焦虑水平下,50毫克D - 环丝氨酸可改善这项具有挑战性的视觉空间认知任务的表现。当焦虑水平较高时,未观察到表现的提升,且D - 环丝氨酸似乎并未增加主观焦虑。这些数据支持将D - 环丝氨酸及相关谷氨酸增强剂用作认知调节剂,并表明D - 环丝氨酸的作用并非仅仅与唤醒或焦虑增加有关。